
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9575542/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to: â€~Correspondence on â€~Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng. Annals of the Rheumatic Diseases, 2023, 82, e94-e94.	0.9	2
2	Response to: â€~Correspondence on â€~Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e143-e143.	0.9	1
3	Assessment of minor health disorders with decision tree-based triage in community pharmacies. Research in Social and Administrative Pharmacy, 2022, 18, 2867-2873.	3.0	6
4	Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. Rheumatology, 2022, 61, 1448-1458.	1.9	12
5	The association between bariatric surgery and cataract: a propensity score-matched cohort study. Surgery for Obesity and Related Diseases, 2022, 18, 217-224.	1.2	1
6	The association of bariatric surgery and Dupuytren's disease: a propensity score-matched cohort study. Journal of Hand Surgery: European Volume, 2022, 47, 288-295.	1.0	3
7	Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 207-220.	11.4	123
8	Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients. Journal of Clinical Medicine, 2022, 11, 397.	2.4	15
9	Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study. American Journal of Medicine, 2022, 135, 879-888.e3.	1.5	7
10	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Rheumatology Advances in Practice, 2022, 6, rkac010.	0.7	0
11	Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland. BMJ Open, 2022, 12, e056352.	1.9	2
12	The associations between bariatric surgery and hip or knee arthroplasty, and hip or knee osteoarthritis: Propensity score-matched cohort studies. Osteoarthritis and Cartilage Open, 2022, 4, 100249.	2.0	1
13	Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection. Scientific Reports, 2022, 12, 7843.	3.3	5
14	Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review. Osteoporosis International, 2022, , .	3.1	4
15	Opioid sales and opioid-related poisonings in Switzerland: A descriptive population-based time-series analysis. Lancet Regional Health - Europe, The, 2022, 20, 100437.	5.6	5
16	Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: A population-based cohort study. Diabetes Research and Clinical Practice, 2022, 190, 109993.	2.8	7
17	Association between osteoporosis and statins therapy: the story continues. Annals of the Rheumatic Diseases, 2021, 80, e204-e204.	0.9	3
18	Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. European Child and Adolescent Psychiatry, 2021, 30, 1047-1058.	4.7	3

#	Article	IF	CITATIONS
19	Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice. European Journal of Clinical Pharmacology, 2021, 77, 709-716.	1.9	7
20	Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 2021, 80, 423-431.	0.9	21
21	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporosis International, 2021, 32, 817-829.	3.1	21
22	Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data. European Journal of Clinical Pharmacology, 2021, 77, 913-919.	1.9	4
23	Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making. Journal of Clinical Medicine, 2021, 10, 1140.	2.4	23
24	Primary and secondary non-response: in need of operational definitions in observational studies. Annals of the Rheumatic Diseases, 2021, 80, 961-964.	0.9	18
25	Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Journal of Clinical Medicine, 2021, 10, 1660.	2.4	26
26	POS0122â€THE ASSOCIATIONS BETWEEN DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND INCIDENT, AND PROGRESSION OF, RADIOGRAPHIC HAND OSTEOARTHRITIS IN RHEUMATOID ARTHRITIS PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 272.2-273.	0.9	0
27	POS0011â€THE ASSOCIATION BETWEEN BARIATRIC SURGERY AND CARPAL TUNNEL SYNDROME: A COHORT STUDY FROM SWEDISH NATIONWIDE HEALTHCARE REGISTRIES. Annals of the Rheumatic Diseases, 2021, 80, 207.2-208.	0.9	0
28	POS1383â€THE ASSOCIATION BETWEEN BARIATRIC SURGERY AND DUPUYTREN DISEASE: A COHORT STUDY FROM SWEDISH NATIONWIDE HEALTHCARE REGISTRIES. Annals of the Rheumatic Diseases, 2021, 80, 974.3-975.	0.9	0
29	Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study. Diabetes Research and Clinical Practice, 2021, 176, 108828.	2.8	0
30	Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. Journal of Clinical Medicine, 2021, 10, 3194.	2.4	8
31	Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients. Journal of Clinical Medicine, 2021, 10, 3200.	2.4	7
32	Thiazolidinediones and Glucagonâ€Like Peptideâ€1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology, 2021, 74, 2467-2477.	7.3	10
33	A Network Analysis of Drug Combinations Associated with Acute Generalized Exanthematous Pustulosis (AGEP). Journal of Clinical Medicine, 2021, 10, 4486.	2.4	8
34	Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 267.	3.5	4
35	Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients. Rheumatology Advances in Practice, 2021, 5, rkab087.	0.7	4
36	Community Pharmacist-Administered COVID-19 Vaccinations: A Pilot Customer Survey on Satisfaction and Motivation to Get Vaccinated. Vaccines, 2021, 9, 1320.	4.4	16

#	Article	IF	CITATIONS
37	When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Frontiers in Endocrinology, 2021, 12, 782118.	3.5	14
38	Fracture Patterns in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review of Recent Literature. Current Osteoporosis Reports, 2021, 19, 644-655.	3.6	16
39	The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population-Based Cohort Study. Journal of the American Medical Directors Association, 2020, 21, 811-816.	2.5	9
40	Community pharmacist-administered seasonal influenza vaccination: a national customer survey. Journal of Pharmaceutical Policy and Practice, 2020, 13, 57.	2.4	4
41	Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature. Journal of Clinical Medicine, 2020, 9, 3342.	2.4	11
42	National Poison Center Calls Before vs After Availability of High-Dose Acetaminophen (Paracetamol) Tablets in Switzerland. JAMA Network Open, 2020, 3, e2022897.	5.9	3
43	Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase. Drug Safety, 2020, 43, 881-891.	3.2	32
44	Drug utilization in the Maastricht Study. Medicine (United States), 2020, 99, e18524.	1.0	1
45	Medication as a risk factor for hospitalization due to heart failure and shock: a series of case-crossover studies in Swiss claims data. European Journal of Clinical Pharmacology, 2020, 76, 979-989.	1.9	2
46	Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010. Osteoporosis International, 2019, 30, 2217-2223.	3.1	23
47	Time trends in oral bisphosphonate initiation in Ontario, Canada over 20Âyears reflect drug policy and healthcare delivery changes. Osteoporosis International, 2019, 30, 2311-2319.	3.1	11
48	Mortality risk in atrial fibrillation: the roleÂof aspirin, vitamin K and non-vitamin K antagonists. International Journal of Clinical Pharmacy, 2019, 41, 1536-1544.	2.1	4
49	Pharmacoepidemiology and Big Data Analytics: Challenges and Opportunities when Moving towards Precision Medicine. Chimia, 2019, 73, 1012.	0.6	4
50	Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease. Bone, 2018, 110, 238-243.	2.9	13
51	Risk of a firstâ€ever acute myocardial infarction and allâ€eause mortality with sulphonylurea treatment: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 1056-1060.	4.4	8
52	Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Archives of Osteoporosis, 2018, 13, 30.	2.4	43
53	Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. Pharmacoepidemiology and Drug Safety, 2018, 27, 1191-1199.	1.9	17
54	Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK. Cancer Epidemiology, 2018, 54, 104-111.	1.9	18

4

#	Article	IF	CITATIONS
55	Increased risk of all ause mortality associated with domperidone use in Parkinson's patients: a populationâ€based cohort study in the UK. British Journal of Clinical Pharmacology, 2018, 84, 2551-2561.	2.4	10
56	Association between use of antidepressants or benzodiazepines and the risk of subsequent fracture among those aged 65+ in the Netherlands. Osteoporosis International, 2018, 29, 2477-2485.	3.1	11
57	Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology, 2018, 57, 1641-1650.	1.9	34
58	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. British Journal of Clinical Pharmacology, 2017, 83, 1844-1859.	2.4	17
59	Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1402-1404.	5.6	99
60	Impact of detection bias on the risk of gastrointestinal cancer and its subsites in type 2 diabetes mellitus. European Journal of Cancer, 2017, 79, 61-71.	2.8	13
61	Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. British Journal of Clinical Pharmacology, 2017, 83, 1835-1843.	2.4	10
62	No Decreased Risk of Gastrointestinal Cancers in Users of Metformin in The Netherlands; A Time-Varying Analysis of Metformin Exposure. Cancer Prevention Research, 2017, 10, 290-297.	1.5	24
63	Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ, The, 2016, 354, i3625.	6.0	65
64	Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: the effect of index date selection?. Annals of the Rheumatic Diseases, 2016, 75, e26-e26.	0.9	1
65	Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?. Lancet Respiratory Medicine,the, 2015, 3, e38-e39.	10.7	0
66	Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiology and Drug Safety, 2015, 24, 67-74.	1.9	26
67	Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs. Pharmacoepidemiology and Drug Safety, 2015, 24, 1017-1025.	1.9	30
68	Initial uptake of the Ontario Pharmacy Smoking Cessation Program. Canadian Pharmacists Journal, 2015, 148, 29-40.	0.8	16
69	Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporosis International, 2015, 26, 1525-1533.	3.1	13
70	Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs. Calcified Tissue International, 2015, 97, 506-515.	3.1	56
71	Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporosis International, 2015, 26, 1831-1840.	3.1	41
72	Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis. Calcified Tissue International, 2015, 97, 104-112.	3.1	56

#	Article	IF	CITATIONS
73	Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. Journal of Clinical Epidemiology, 2015, 68, 950-956.	5.0	318
74	Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study. CMAJ Open, 2015, 3, E91-E96.	2.4	6
75	Examining Exposure Misclassification of Oral Bisphosphonate Therapy and the Associated Fracture Risk: A Cohort Study. Advances in Pharmacoepidemiology & Drug Safety, 2015, 04, .	0.1	Ο
76	Variation in the days supply field for osteoporosis medications in Ontario. Archives of Osteoporosis, 2013, 8, 128.	2.4	11
77	Caseâ€crossover study design in pharmacoepidemiology: systematic review and recommendations. Pharmacoepidemiology and Drug Safety, 2013, 22, 1146-1153.	1.9	47
78	Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporosis International, 2012, 23, 1075-1082.	3.1	40
79	The Burden of Osteoporosis in Canada. Canadian Pharmacists Journal, 2011, 144, S3-S3.e1.	0.8	5
80	An Eight Component Decision-Making Model for Problem Gambling:A Systems Approach to Stimulate Integrative Research. Journal of Gambling Studies, 2011, 27, 523-563.	1.6	20
81	The impact of pharmacist interventions on osteoporosis management: a systematic review. Osteoporosis International, 2011, 22, 2587-2596.	3.1	48
82	Measuring and improving adherence to osteoporosis pharmacotherapy. Current Opinion in Rheumatology, 2010, 22, 397-403.	4.3	38